{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:46:58Z","timestamp":1790066818440,"version":"4.0.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T00:00:00Z","timestamp":1303776000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0019164","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T21:35:27Z","timestamp":1303853727000},"page":"e19164","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro"],"prefix":"10.1371","volume":"6","author":[{"given":"Stefan","family":"Balabanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Gontarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Raddrizzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Braig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bosotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Barett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Rohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,4,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.","volume":"145","author":"HM Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"BJ Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.","volume":"108","author":"L Roy","year":"2006","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.","volume":"16","author":"A Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.","volume":"101","author":"NJ Donato","year":"2003","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.","volume":"92","author":"C Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V99.2.713","article-title":"Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.","volume":"99","author":"HG Jorgensen","year":"2002","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.","volume":"21","author":"C Brendel","year":"2007","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.","volume":"108","author":"NE Jordanides","year":"2006","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2174\/156800906779010209","article-title":"Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.","volume":"6","author":"E Ritchie","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"M Deininger","year":"2005","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"NP Shah","year":"2004","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"E Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.","volume":"66","author":"M Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"ref16","first-page":"119","article-title":"Keller G, Schafhausen P, Brummendorf TH Bosutinib.","volume":"184","journal-title":"Recent Results Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.moh.0000148551.93303.9e","article-title":"Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.","volume":"12","author":"J Goldman","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00109-007-0241-y","article-title":"Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia\u2014insights from mathematical model analyses.","volume":"86","author":"I Roeder","year":"2008","journal-title":"J Mol Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603603","article-title":"Leukaemia stem cells: hit or miss?","volume":"96","author":"I Glauche","year":"2007","journal-title":"Br J Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1634\/stemcells.2006-0136","article-title":"Successful therapy must eradicate cancer stem cells.","volume":"24","author":"D Dingli","year":"2006","journal-title":"Stem Cells"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"SM Graham","year":"2002","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"M Copland","year":"2006","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.","volume":"109","author":"HG Jorgensen","year":"2007","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606.","volume":"111","author":"H Konig","year":"2008","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.","volume":"101","author":"R Bhatia","year":"2003","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358) - A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor.","volume":"184","author":"A Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.","volume":"111","author":"A Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1158\/0008-5472.CAN-07-1825","article-title":"Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.","volume":"67","author":"M Modugno","year":"2007","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","article-title":"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.","volume":"6","author":"P Carpinelli","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4161\/cc.4.3.1560","article-title":"A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.","volume":"4","author":"N von Bubnoff","year":"2005","journal-title":"Cell Cycle"},{"key":"ref31","author":"HD Jorge Cortes-Franco","year":"2009"},{"issue":"Suppl 4","key":"ref32","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","article-title":"The chronic myeloid leukemia stem cell.","volume":"9","author":"E Nicholson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/CBM-2007-34-503","article-title":"Stem cells in chronic myeloid leukaemia.","volume":"3","author":"F Pellicano","year":"2007","journal-title":"Cancer Biomark"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance.","volume":"104","author":"J Thomas","year":"2004","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump.","volume":"104","author":"H Burger","year":"2004","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.","volume":"21","author":"X Jiang","year":"2007","journal-title":"Leukemia"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.","volume":"103","author":"S Chu","year":"2004","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2009.242","article-title":"Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.","volume":"24","author":"DK Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2005-03-037648","article-title":"Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.","volume":"109","author":"S Balabanov","year":"2007","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.","volume":"94","author":"T Holyoake","year":"1999","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data.","volume":"4","author":"RA Irizarry","year":"2003","journal-title":"Biostatistics"},{"key":"ref42","article-title":"A model based background adjustment for oligonucleotide expression arrays.","author":"IR Wu Z","year":"2004"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0019164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T16:53:37Z","timestamp":1592499217000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0019164"}},"subtitle":[],"editor":[{"given":"Venugopalan","family":"Cheriyath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,26]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0019164","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,26]]}}}